Breast cancer and NSAID use: a meta-analysis

Area of Science:

• Epidemiology
• Oncology
• Pharmacology

Background:

• Epidemiological studies suggest non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of various cancers, including breast cancer.
• Understanding the potential chemopreventive effects of NSAIDs is crucial for public health strategies.
• Previous research indicates a possible link between NSAID use and decreased cancer incidence.

Purpose of the Study:

• To conduct a meta-analysis of existing studies examining the association between NSAID use and breast cancer risk.
• To quantify the overall relative risk (RR) of breast cancer associated with NSAID consumption.
• To evaluate the consistency of findings across different study designs (cohort and case-control).

Main Methods:

• Systematic abstraction of relative risk estimators and variances from relevant epidemiological studies.
• Inclusion of studies with confounder adjustment for robust analysis.
• Calculation of combined RRs using fixed or random effect models for cohort and case-control studies separately and combined.

Main Results:

• The overall meta-analysis of 14 studies (6 cohort, 8 case-control) showed a combined RR of 0.82 (95% CI = 0.75-0.89) for breast cancer with NSAID use.
• The RR for cohort studies was 0.78 (95% CI = 0.62-0.99), and for case-control studies, it was 0.87 (95% CI = 0.84-0.91).
• A statistically significant reduction in breast cancer risk was observed with NSAID use.

Conclusions:

• NSAID use appears to be associated with a modest reduction in breast cancer risk.
• The current data are insufficient to establish dose-response relationships for NSAID duration, frequency, or specific drug types.
• Further investigation is warranted to elucidate optimal NSAID regimens for breast cancer prevention.